Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397343 | 0.87 | ALDH1A1 (0.51) | ALDH1A1TSHRKDM4EHSD17B10LMNA | |
| SCHEMBL435164 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TSHRKDM4EHSD17B10LMNA | |
| SCHEMBL1169912 | 0.84 | ALDH1A1 (0.51) | ALDH1A1TSHRKDM4EHSD17B10LMNA | |
| SCHEMBL395741 | 0.83 | PTGES (0.48) | ALDH1A1TSHRKDM4EHSD17B10LMNA | |
| SCHEMBL395742 | 0.83 | PTGES (0.48) | ALDH1A1TSHRKDM4EHSD17B10LMNA | |
| SCHEMBL1170425 | 0.82 | KMT2A (0.45) | ALDH1A1TSHRKDM4EHSD17B10LMNA | |
| SCHEMBL1170426 | 0.82 | KMT2A (0.45) | ALDH1A1TSHRKDM4EHSD17B10LMNA | |
| SCHEMBL393917 | 0.81 | KMT2A (0.49) | ALDH1A1TSHRKDM4EHSD17B10LMNA | |
| SCHEMBL393916 | 0.81 | KMT2A (0.49) | ALDH1A1TSHRKDM4EHSD17B10LMNA | |
| SCHEMBL12867415 | 0.81 | KMT2A (0.49) | ALDH1A1TSHRKDM4EHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604025-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8367661-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232092-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. | 2012-09-13 | — | — | US | disclosed |
| US-8202859-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100069370-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-7595322-B2 | Heterocyclic sulfonamides as modulators of cardiac sarcomeres | CYTOKINETICS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1605752-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070078126-A1 | Useful in selective modulation of cardiac sarcomere, for example, by potentiating cardiac myosin; can be used to treat heart failure including CHF, particularly systolic heart failure; 4-[4-chloro-3-(5-phenyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-benzenesulfonyl]-piperazine-1-carboxylic acid ethyl ester | CYTOKINETICS, INCORPORATED | 2007-04-05 | — | — | US | disclosed |
| EP-1605752-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004086865-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | ALDH1A1 4297/4885TSHR 3581/4885KDM4E 2012/4885 |
| US-20100069370-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNT2, MYLK2 | ALDH1A1 4510/4885TSHR 4440/4885KDM4E 2431/4885 |
| US-20070078126-A1 | Useful in selective modulation of cardiac sarcomere, for example, by potentiating cardiac myosin; can be used to treat heart failure including CHF, particularly systolic heart failure; 4-[4-chloro-3-(5-phenyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-benzenesulfonyl]-piperazine-1-carboxylic acid ethyl ester | MYLK2, MYH2, MYH14 | ALDH1A1 3016/4885TSHR 3736/4885KDM4E 757/4885 |
| US-20120232092-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | ALDH1A1 4297/4885TSHR 3581/4885KDM4E 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.